Hoth Therapeutics Reports Favorable Results for First-of-Its-Kind HT-001 Treatment of a Patient

By MarketWatch | Sep 5, 2024 at 02:15 PM EST

Hoth Therapeutics stock surged 49% after positive results for HT-001 in treating skin toxicities from cancer drugs. A patient saw rapid improvement and stopped treatment after a week. The company received approval for a Phase 2a trial from two medical centers.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.